said fourth-quarter earnings will include a charge of $245 million, or 40 cents a share, mostly to cover the suspension of a flu-vaccine trial.
Before the items, the company still expects to earn 54 cents to 58 cents a share. Analysts are expecting the company to earn 56 cents a share in the quarter, before charges, according to Thomson First Call. Baxter will unveil its financial results Jan. 27.
Last month, Baxter suspended enrollment in a test for its PreFluCel influenza vaccine, due to a higher-than-expected rate of mild fever and associated symptoms in clinical trial participants.
The company said it was taking a one-time charge "due to uncertainty regarding the ultimate successful commercialization of an influenza vaccine, and in accordance with generally accepted accounting principles."
The vaccine-related charge is $170 million for a writedown of certain assets related to the vaccine program.
Baxter also expects to record a one-time charge of $45 million for the write-down of assets related to the development of a drug, Epomax, for treating anemia and a $30-million charge for the write-down of excess manufacturing assets in Thousand Oaks, Calif.
Baxter's stock dropped 48 cents, or 1.4%, to $35.